# Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old

> **NCT00439660** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bharat Biotech International Limited** · enrollment: 540 (actual)

## Conditions studied

- Diarrhea

## Interventions

- **BIOLOGICAL:** Oral Rotavirus Vaccine 116E Live Attenuated

## Key facts

- **NCT ID:** NCT00439660
- **Lead sponsor:** Bharat Biotech International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2021-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00439660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00439660, "Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00439660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*